操到底了继续干20p_国产九一在线_婷婷成人五月天开心激情_欧美黄色免费公开视频_清纯唯美 亚洲_亚洲综合影音先锋_jk白丝自慰五月天综合网_天下第一视频日本社区WWW_日本最新电影在线_日韩中文人妻无码不卡2017

One more step in Kexing Biopharm's R&D!

On the evening of August 14, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "Human Interferon α2b Spray" was accepted.

Basic Information of the Drug for Registration

1.  Product Name: Human Interferon α2b Spray
2. Application Item: clinical trial for registration of drugs produced in China
3. Acceptance No.: CXSL2200374G
4. Indication: It is proposed for the treatment of initial or recurrent skin herpes simplex (oral herpes and genital herpes) caused by virus.
5. Dosage Form: spray

The promotion of the R&D of Human Interferon α2b Spray will help the Company further optimize the product portfolio, enrich the product pipelines, enhance the overall R&D capability, and build up the long-term profitability.

About Human Interferon α2b Spray
Human Interferon α2b Spray is a Class 2 modified new drug, independently developed by the Company, with optimized dosage form and administration route compared with the drugs already on the market. It has the obvious clinical advantages of increased drug concentration at the lesions through targeted local administration, convenient use and carrying, and good patient compliance. The Human Interferon α2b Spray is indicated for the treatment of initial or recurrent skin herpes simplex (oral herpes and genital herpes) caused by virus.